TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 17

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Background

A CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) has become standard of care in first-line estrogen receptor–positive (ER+)/HER2-negative (HER2–) advanced breast cancer (ABC). Despite significant improvements in survival, these patients will eventually experience disease progression. Optimal treatment sequence following progression on CDK4/6i plus ET has not yet been established and is dependent on various factors. Thus, new targeted treatments are needed for patients with ET-resistant ABC. [177Lu]Lu-NeoB (177Lu-NeoB) is a first-in-class radioligand therapy that binds selectively to GRPR. NeoRay is a first-in-human trial testing 177Lu-NeoB in advanced solid tumors. We describe the CAAA603D12101 study (NeoB D1), a phase 1/2, open-label, multicenter study evaluating 177Lu-NeoB plus capecitabine, a known radiosensitizer, in patients with ER+/HER2− ABC with GRPR expression after progression on prior ET plus CDK4/6i.

Materials and Methods

NeoB D1 includes dose-escalation and dose-optimization for 177Lu-NeoB. Eligible patients include adult men and pre/peri/postmenopausal women with ER+/HER2− ABC. Patients can have received 1 to 3 prior lines of ET for ABC, 1 of which is required to have included a CDK4/6i. For patients with a BRCA1/2 mutation, prior treatment with a PARP inhibitor is allowed. For patients with HER2-low disease, prior treatment with trastuzumab deruxtecan is allowed.

In phase 1, patients will receive 177Lu-NeoB at 150 millicurie (mCi) every 6 weeks (Q6W) plus capecitabine (1000 mg/m2 by mouth for 14 days, followed by 7 days off). If dose escalation is supported, then patients will be randomized to the 2 higher dose levels (200 mCi Q6W or 100 mCi Q3W); if dose escalation is not supported, then lower levels will be explored. Phase 2 will randomize patients to 2 dose levels of 177Lu-NeoB plus capecitabine based on multiple different scenarios. Treatment duration of 177Lu-NeoB is planned to be 6 administrations for the Q6W regimen and 12 administrations for the Q3W regimen.

The primary objectives of the dose-escalation are incidence and severity of dose-limiting toxicities and adverse effects and dose modifications of 177Lu-NeoB plus capecitabine. The primary objectives of the dose-optimization are objective response rate, clinical benefit rate, time to response, duration of response, progression-free survival, and overall survival. Secondary objectives include PK and biodistribution. Planned enrollment is about 58 patients. Enrollment is currently open. ClinicalTrials.gov ID: NCT06247995.

Status

Currently enrolling.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content